Macular retinal edema

FDA Grants Regeneron Two Eylea HD Approvals in One Day

3 weeks ago talkbio0Tagged aflibercept, Approved, dosing, Eylea, Hodgkin Disease, Macular retinal edema, monthly, Ophthalmology specialty, Regeneron, Retinal Vein Occlusion, RVO, United States Food and Drug Administration

Regeneron; FDA approval; Eylea HD; macular edema; retinal vein occlusion; monthly dosing; aflibercept; ophthalmology; RVO

FDA Approves New Indication and Monthly Dosing for Regeneron’s Eylea HD

3 weeks ago talkbio0Tagged aflibercept, Approved, dosing, Eylea, Hodgkin Disease, Macular retinal edema, monthly, Ophthalmology specialty, Pre-filled Syringe, Regeneron, Retinal Diseases, Retinal Vein Occlusion, United States Food and Drug Administration

FDA approval; Eylea HD; Regeneron; macular edema; retinal vein occlusion; monthly dosing; ophthalmology; aflibercept; retinal diseases; pre-filled syringe

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

12 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition